AiCuris’ Pritelivir Granted FDA Priority Review, New Data
The FDA has granted Priority Review to AiCuris’ new drug application for pritelivir, an oral helicase-primase inhibitor for refractory...
No videos found.
Tilray’s Lyphe Bet Isn’t About Europe — It’s About Being Ready When Washington Moves
Tilray's Lyphe acquisition signals a deliberate commercial build for U.S. cannabis rescheduling — and most competitors are structurally unprepared...
The Trusted Source: How Veeva’s Acquisition of Ostro Is Rewriting How Patients and Doctors Get Drug Information
Veeva Systems — the enterprise software giant that has long dominated clinical, regulatory, and commercial operations for life sciences...
China Biotech Dealmaking Shifts from Opportunistic to Strategic
At BIO-Europe Spring 2026, industry leaders from AstraZeneca, Kelun-Biotech, Harbour BioMed, and Panacea Capital dissected the structural forces driving...
Novo Nordisk’s OpenAI Deal Isn’t About Drug Discovery — It’s About Owning the Next Cost Curve
Novo Nordisk's OpenAI partnership signals a new pharma AI arms race where pipeline economics, not just science, get rebuilt...
BioNTech’s Endometrial ADC Data Is Not a Science Story — It’s a $3 Billion Market Access Problem in Disguise
Trastuzumab pamirtecan just posted compelling Phase 2 numbers in HER2-expressing recurrent endometrial cancer. The science is clean. The commercial...
AI Rewires Biopharma BD — From Data Grunt to Strategic Lever
At BIO-Europe Spring 2026, a cross-sector panel dissected how generative AI is restructuring the business development workflow — from...
Oricell’s $110 Million Bet Exposes the Dirty Secret of Solid Tumor CAR-T: The Science Is Ahead of the Business Model
Oricell Therapeutics just closed a $110 million pre-IPO round to push its CAR-T platform into solid tumors. Investors are...
ImmuCell Announces Surging Q1 2026 Sales Growth of 28.4%
ImmuCell posted preliminary first-quarter 2026 sales of $10.4 million, up 28.4% year over year, propelled by its Tri-Shield First...
Remedy Plan Therapeutics Appoints New Finance, Business Chief
Remedy Plan Therapeutics has appointed Jotin Marango, M.D., Ph.D., as Chief Financial and Business Officer as the company transitions...